Tesetaxel as First-line Therapy for Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The intravenously administered taxane, paclitaxel, is one of the most commonly employed
agents for the treatment of both localized and advanced breast cancer.
Tesetaxel is an orally administered taxane that is in development as first- and second-line
treatment for patients with advanced cancers. This study is being undertaken to determine the
efficacy and safety of tesetaxel administered as first-line therapy to patients with
metastatic breast cancer.